Featured
Neuroscience needs a research-video archive
Inclusivity committee disbands in protest at Canadian neuroscience institute
How to explore your scientific values and develop a vision for your field
Latest
What neuroscientists should know—and what they can do—about changes to BRAIN initiative funding
Carol Jennings, whose family’s genetics informed amyloid cascade hypothesis, dies at 70
‘These are not alternative careers’: More neuroscience Ph.D. programs start to facilitate industry internships
Today’s action potentials
”We have not, as a community, talked about what comes next. If we want this type of funding to continue in some form in a sustainable way, it will take advocacy from the community. — CHRISTOPHER ROZELL
Crowdsourcing to curb aggression in autism: Q&A with Matthew Goodwin
RNA drug corrects calcium signaling in chimeric model of Timothy syndrome
To improve big data, we need small-scale human imaging studies
What, if anything, makes mood fundamentally different from memory?
Boost your writing with AI personas
Synaptic
The value of math and spatial learning with Loren Frank
Setting up a frog colony and pair bonding with Lauren O’Connell
Being uncomfortable and PKMzeta with André Fenton
From bench to bot: How to use AI to structure your writing
From bench to bot: How to use AI tools to convert notes into a draft
From bench to bot: A scientist’s guide to AI-powered writing
Larry Young built bridges with his social neuroscience research
Known for his work bringing oxytocin studies to the mainstream, Young died unexpectedly last month.
The legacy of William Catterall, ‘father of ion channels’
Maiken Nedergaard’s power of disruption
Unleashing the power of DIY innovation in behavioral neuroscience
Pooling data points to new potential treatment for spinal cord injury
How scuba diving helped me embrace open science
Making cancer nervous
Nerve cells in the brain and throughout the body can turbocharge tumor growth — a finding that not only expands conventional ideas about the nervous system but points to novel therapeutic targets for a range of malignancies.
Uncertainty and excitement surround one company’s cell therapy for epilepsy
After 10 years of work, Neurona may have the data to quiet its skeptics. But its ongoing clinical trial will be the ultimate test.